Analysis of the Factors Contributing to Bariatric Success After Laparoscopic Redo Bariatric Procedures: Results from Multicenter Polish Revision Obesity Surgery Study (PROSS)

Introduction

With continuously growing number of redo bariatric surgeries (RBS), it is necessary to look for factors determining success of redo-surgeries.

Patients and methods

A retrospective cohort study analyzed consecutive patients who underwent RBS in 12 referral bariatric centers in Poland from 2010 to 2020. The study included 529 patients. The efficacy endpoints were percentage of excessive weight loss (%EWL) and remission of hypertension (HT) and/or type 2 diabetes (T2D).

Results

Group 1: weight regain

Two hundred thirty-eight of 352 patients (67.6%) exceeded 50% EWL after RBS. The difference in body mass index (BMI) pre-RBS and lowest after primary procedure < 10.6 kg/m2 (OR 2.33, 95% CI: 1.43–3.80, p = 0.001) was independent factor contributing to bariatric success after RBS, i.e., > 50% EWL.

Group 2: insufficient weight loss

One hundred thirty of 177 patients (73.4%) exceeded 50% EWL after RBS. The difference in BMI pre-RBS and lowest after primary procedure (OR 0.76, 95% CI: 0.64–0.89, p = 0.001) was independent factors lowering odds for bariatric success.

Group 3: insufficient control of obesity-related diseases

Forty-three of 87 patients (49.4%) achieved remission of hypertension and/or type 2 diabetes. One Anastomosis Gastric Bypass (OAGB) as RBS was independent factor contributing to bariatric success (OR 7.23, 95% CI: 1.67–31.33, p = 0.008), i.e., complete remission of HT and/or T2D.

Conclusions

RBS is an effective method of treatment for obesity-related morbidity. Greater weight regain before RBS was minimizing odds for bariatric success in patients operated due to weight regain or insufficient weight loss. OAGB was associated with greater chance of complete remission of hypertension and/or diabetes.

Graphical abstract

     

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial

Patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndrome (MDS) or higher-risk MDS have limited treatment options and poor prognosis. Our previous single-center study of decitabine followed by low dose idarubicin and cytarabine (D-IA) in patients with myeloid neoplasms showed promising primary results. We therefore conducted a multicenter study of D-IA regimen in AML evolving from MDS and higher-risk MDS. Patients with AML evolving from MDS or refractory anemia with excess blasts type 2 (RAEB-2) (based on the 2008 WHO classification) were included. The D-IA regimen (decitabine, 20 mg/m² daily, days 1 to 3; idarubicin, 6 mg/m² daily, days 4 to 6; cytarabine 25 mg/m² every 12 hours, days 4 to 8; granulocyte colony stimulating factor [G-CSF], 5 μg/kg, from day 4 until neutrophil count increased to 1.0 × 10⁹/L) was administered as induction chemotherapy. Seventy-one patients were enrolled and treated, among whom 44 (62.0%) had AML evolving from MDS and 27 (38.0%) had RAEB-2. Twenty-eight (63.6%) AML patients achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi): 14 (31.8%) patients had CR and 14 (31.8%) had CRi. Six (22.2%) MDS patients had CR and 15 (55.6%) had marrow complete remission. The median overall survival (OS) was 22.4 months for the entire group, with a median OS of 24.2 months for AML and 20.0 months for MDS subgroup. No early death occurred. In conclusion, the D-IA regimen was effective and well tolerated, representing an alternative option for patients with AML evolving from MDS or MDS subtype RAEB-2.     

循经针刺与同神经节段针刺治疗神经根型颈椎病临床观察

目的:对比循经针刺与同神经节段针刺治疗神经根型颈椎病的疗效。方法:120例随机分为治疗组和对照组各60例,治疗组用同神经节段针刺治疗,对照组用循经针刺治疗。结果:显效率治疗组81.7%、对照组61.7%,两组显效率比较差异有统计学意义(P<0.05)。结论:两种方法治疗神经根型颈椎病均有良好的疗效,同神经节段针刺治疗神经根型颈椎病疗效优于"循经针刺"。     

新形势下八年制医学教育的再思考

新形势下，健康中国建设和我国卫生事业发展迫切需要具有国际竞争力的医学科学家和领军人才。在现行医学教育体系中，培养具有国际竞争力的未来医学科学家和领军人才是八年制医学教育的必然选择。创新八年制医学人才培养模式应汲取长学制试办经验，直面现存问题，聚焦创新能力和创新精神，构建以研究为基础的八年制医学人才培养模式，确立“目标引领、厚植基础、面向临床、聚集创新”的办学原则，为我国卫生事业培养具有国际竞争力的未来领军人才。     

Host–microbiome interactions: the aryl hydrocarbon receptor as a critical node in tryptophan metabolites to brain signaling

ABSTRACT

Tryptophan (Trp) is not only a nutrient enhancer but also has systemic effects. Trp metabolites signaling through the well-known aryl hydrocarbon receptor (AhR) constitute the interface of microbiome-gut-brain axis. However, the pathway through which Trp metabolites affect central nervous system (CNS) function have not been fully elucidated. AhR participates in a broad variety of physiological and pathological processes that also highly relevant to intestinal homeostasis and CNS diseases. Via the AhR-dependent mechanism, Trp metabolites connect bidirectional signaling between the gut microbiome and the brain, mediated via immune, metabolic, and neural (vagal) signaling mechanisms, with downstream effects on behavior and CNS function. These findings shed light on the complex Trp regulation of microbiome-gut-brain axis and add another facet to our understanding that dietary Trp is expected to be a promising noninvasive approach for alleviating systemic diseases.     

新疆乌鲁木齐地区新生儿眼底病筛查情况报告

目的 了解新疆乌鲁木齐地区新生儿眼底病的发病情况，为新生儿眼底病防治提供依据。设计 横断面研究。研究对象 乌鲁木齐市妇幼保健院2014年1月至2018年12月出生的新生儿25 644例。方法 对所有新生儿应用广域数字化眼底成像系统 （RetCam3） 进行眼底检查，记录所有受检患儿出生孕周、出生体重、分娩方式等临床资料，对筛查结果进行分析。主要指标 眼底异常的发生率。结果 446例新生儿眼底异常，异常率达18.16%。其中视网膜出血3334例（13.00%），经阴道分娩新生儿视网膜出血发病率（20.91%）明显高于剖宫产（3.71%）（P=0.000）；家族性渗出性玻璃体视网膜病变87例（0.34%）；视网膜周边白色病灶539例（2.1%）；永存原始玻璃体增生症4例（0.02%）；牵牛花综合征6例（0.02%）；视网膜母细胞瘤2例（0.01%）；在1649例早产儿中检出早产儿视网膜病变79例（4.79%），其中检出率与出生胎龄及出生体重均呈负相关（r=-0.879、-0.907，P=0.049、0.034）。结论 乌鲁木齐地区新生儿眼底疾病发病率排在前几位的眼病都是非致盲性、非紧急、无需干预的告知性眼病，主要的致盲性眼底疾病仍是以早产儿视网膜病变为主。     

A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia

Cancer Chemotherapy and Pharmacology - To evaluate the predictive value of the in vitro chemosensitivity using ATP-TCA method to compare the clinical efficacy of patients with AML. Bone marrow or...     

Correction to: The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score

Clinical Rheumatology - In the original version of the above article the References 19 and 20 were incorrect which cannot describe the development of the SPARCC score.